Nucl Med Mol Imaging.  2022 Dec;56(6):313-322. 10.1007/s13139-022-00778-y.

Preparation of Patient Doses of ­[¹⁷⁷Lu]Lu‑DOTATATE and ­[¹⁷⁷Lu] Lu‑PSMA‑617 with Carrier Added (CA) and No Carrier Added (NCA) ¹⁷⁷Lu

• Nanabala R
• Pillai M
• Gopal B

• KMID: 2537091
• DOI: http://doi.org/10.1007/s13139-022-00778-y

Abstract

Purpose
[¹⁷⁷Lu]Lu-DOTATATE and ­[¹⁷⁷Lu]Lu-PSMA-617 used for targeted radionuclide therapy are very often prepared in the hospital radiopharmacy. The preparation parameters vary depending upon the specific activity of the ¹⁷⁷Lu used. The aim of this study was to develop optimized protocols to be used in the nuclear medicine department for the preparation of patient doses of the above radiopharmaceuticals. Method ¹⁷⁷Lu (CA and NCA) were used for radiolabeling DOTATATE and PSMA-617. Parameters studied are ¹⁷⁷Lu of different specific activity and different peptide concentrations and two different buffer systems. Paper and thin layer chromatography systems were used for estimating the radiochemical yield as well as radiochemical purity. Solid-phase extraction was used for the purification of the labeled tracers.
Results
[¹⁷⁷Lu]Lu-DOTATATE was prepared with CA ¹⁷⁷Lu (n = 13) and ­NCA ¹⁷⁷Lu (n = 6). Four batches each of ­[¹⁷⁷Lu] Lu-PSMA-617 were prepared using CA and NCA ¹⁷⁷Lu. Radiochemical yields > 80% and final product with less than < 1% radiochemical impurity could be obtained in all batches which were used for therapy.
Conclusion
Robust protocols for the preparation of clinical doses of ­[¹⁷⁷Lu]Lu-DOTATATE and ­[¹⁷⁷Lu]Lu-PSMA-617 were developed and used for the preparation of clinical doses. The quality of the SPECT images of both the tracers are consistent with the expected uptake in respective diseases.

Keyword

[¹⁷⁷Lu]Lu-DOTATATE; [¹⁷⁷Lu]Lu-PSMA-617; Neuroendocrine tumours; Prostate cancer; Targeted radionuclide therapy